Navigation Links
Drug combination acts against aggressive chronic lymphocytic leukemia
Date:12/10/2012

ATLANTA - A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

Researchers presented the results today at the 54th annual meeting of the American Society of Hematology (ASH).

"This is a patient population with a great need for more targeted therapies," said Jan Burger, M.D., Ph.D., associate professor in MD Anderson's Department of Leukemia. Burger was lead author of the study.

"Many CLL patients, especially those with indolent or non-aggressive disease, do well on the standard treatment of chemotherapy and antibodies," he said. "But for a certain subset of high-risk patients, treatment often fails, and remissions, if they are achieved, are short."

According to the National Cancer Institute's Surveillance Epidemiology and End Results database, CLL is the most common type of adult leukemia in the United States. An estimated 16,000 new cases will be diagnosed this year, and about 4,600 people will die because of the disease. Median age of diagnosis is 72, and it is more common in men than women.

Although chemotherapy combinations have improved the cure rate for CLL, side effects often are severe. A sizeable number of CLL deaths are from secondary cancers caused by treatment.

Early studies showed potential

Ibrutinib, a tyrosine kinase inhibitor that thwarts B-cell receptor signaling, is a promising new targeted therapy for mature B-cell malignancies, including certain types of myeloma and lymphoma. It has been shown to be especially effective in CLL.

Over the past two years, Phase 1/2 trials at MD Anderson and other sites showed high-risk CLL patients responded as well as low-risk patients to ibrutinib. However, the response often is lessened because of persistent lymphocytosis, an
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
2. Combination treatment may improve survival of breast cancer patients with brain metastases
3. Drug combination against NRAS-mutant melanoma discovered
4. Combination peptide therapies might offer more effective, less toxic cancer treatment
5. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
6. BUSM in vitro study identifies potential combination therapy for breast cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Cancer vaccine combination therapy shows survival benefit in breast cancer
10. Combination of 2 drugs reverses liver tumors
11. Immunotherapy for elderly cancer patients finds new promise in drug combination
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug combination acts against aggressive chronic lymphocytic leukemia
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... BOSTON (July 9, 2014) A retrospective study conducted ... and colleagues reports that among adults with intellectual and ... the number of years receiving dental care increased. The ... Care in Dentistry , may help improve interventions designed ... population. , The researchers reviewed the dental records ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... In ... of Technical Personnel in Ophthalmology (ATPO) proudly launched a new tool for ophthalmic professionals: ... , ... Paul, MN (Vocus) November 10, 2009 -- Compact, informative, and convenient are just a ...
... Darden Food Supplier Eliminates Workers Health and Retirement Benefits ... members from Teamster Local Union 890 presented Darden Restaurant Group, ... a letter today directed to Darden CEO Clarence Otis. In ... workers from Hollister, CA are seeking justice after a key ...
... Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: IFLG ... for the healthcare and commercial industries, today announced that ... to NASDAQ,s stockholder approval requirements, in accordance with NASDAQ ... this exception to complete a proposed plan of restructuring, ...
... Nov. 10 Roxane Laboratories, Inc. announced today the ... Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the ... available in bottles of 100 for immediate shipment to ... Tablets are AB rated to ACEON® (perindopril erbumine) tablets. ...
... , ... Rounds -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" ... Gulf Breeze, Fla. (Vocus) November ... Andrews Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at ...
... of vascular risk can be simplified, researchers say ... gauge blood cholesterol to determine vascular disease risk can ... measures levels of either total or high-density lipoprotein (HDL, ... that help transport cholesterol), without the need to have ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:Teamsters Look to Darden Restaurant Group for Justice 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:Cholesterol Measurements May Be Made Easier 2
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... 2012  Stockell Healthcare Systems is pleased to announce ... healthcare provider headquartered in Boulder, Colorado, has selected ... featuring complete Patient Access, Patient Accounting, and Claims ... also selected the MindLinc behavioral health EMR solution ...
... SAN DIEGO, Jan. 5, 2012  Essentialis, Inc., today announced ... with the life sciences-focused venture capital firm Vivo Ventures, ... for his expertise in business development and economic strategies, ... of Directors for Essentialis, a company focused on the ...
Cached Medicine Technology:Mental Health Partners Selects Stockell Healthcare's InsightCS® Revenue Cycle Information Management System 2Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors 2Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors 3
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
... workstations is designed for laboratories with limited ... automation platform for routine sample preparation and ... throughput, process consistency and safety. Windows ... you to control the robotic and liquid ...
... miniGene LD is a reagent dispensing system ... and 1536-well microplates. This dispenser can be ... or wide orifice nozzle heads. Precise plate ... accurate dispensing to a variety of plate ...
Medicine Products: